IGF2BP3 and neoplasm: Therapeutic targeting of this axis is supported by preclinical evidence: combined LINC01559 silencing and osimertinib treatment cooperatively suppressed tumor growth in xenografts, suggesting that disrupting IGF2BP3’s RNA-stabilizing activity could re-sensitize resistant tumors.